Shanghai Bio-Forum Focuses On Patent Protection And Drug Pricing
This article was originally published in PharmAsia News
Executive Summary
Patent protection and drug pricing were hot issues at the recent Conference of Chinese Biopharmaceutical Association and Shanghai Bio-Forum. Delegates agreed that patent protection is a prerequisite of collaboration and represents a key factor that is irreplaceable in the trend of global cooperation. China's laws and regulations on patent and intellectual property protection are well-received but overseas investors and partners expressed concern on the effectiveness of their long-term implementation. Opportunities for collaboration abound in the biopharmaceutical process and China offers the common language of an internationally recognized GMP system. (Click here for more - Chinese Language)
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.